Dr. Reddy's Laboratories announced the launch of Tobramycin Inhalation Solution, USP a therapeutic equivalent generic version of
TOBI (tobramycin) Inhalation Solution, approved by the U.S. Food and Drug Administration.
The TOBI (tobramycin) Inhalation Solution brand and generic had U.S. sales of approximately $97 million MAT for the most recent twelve months ending in April 2019 according to IQVIA Health.
Dr. Reddy's Tobramycin Inhalation Solution, USP is available in a 300 mg/5 ml, single-dose Ampule.
Tobi is a trademark of Mylan.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
